Synthetic Genomics, Janssen Ink RNA Technology Agreement

Synthetic Genomics, Inc. has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., to apply its replicon RNA technology for the design and development of novel RNA-based medicines for infectious diseases. The agreement was facilitated by Johnson & Johnson Innovation. 
 
Synthetic Genomics replicon RNA technology enables a tunable, multigenic approach to elicit desired antigen expression and immune response for a variety of applications. The company believes that this technology will enable the development of RNA-based therapies and vaccines that enhance and fine tune immune response against infectious diseases and cancer.
 
"Our replicon RNA platform is designed to enable controlled expression of antigens and therapeutic proteins to elicit effective immune response against diseases that have historically been difficult to treat or prevent," said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. "Our expertise in programming viral systems to improve upon natural biological processes is uniquely suited to the aspirations of this collaboration with Janssen."